<DOC>
	<DOC>NCT00359944</DOC>
	<brief_summary>The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.</brief_summary>
	<brief_title>Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mild to moderate Alzheimer's Disease Male or female 55 years or older Living with caregiver Read, understand and speak English Need to drive during the study Treatment with acetylcholinesterase inhibitors or NMDA antagonist, such as Aricept or Namenda, within 2 weeks of checkup and during the study Frequent Smoker Frequent Consumer of Caffeine</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Dementia</keyword>
</DOC>